Indeed, atrogin-1 mutations have recently been shown to cause dilated cardiomyopathy due to the upregulation of ER-stress–mediated apoptosis (26), supporting the unsuitability of atrogin-1 inhibition in treating muscle wasting. This evidence concerns the gene FBXO32 and dilated cardiomyopathy.